Beacon Pharmaceutical (New York, N.Y.) said it will launch a new platform to connect terminally ill patients with experimental therapies under the new right-to-try law.
The firm is developing the platform as a philanthropic effort through its venture Beacon Capital arm, which has dedicated $5 million to develop a patient portal with information about accessing the experimental treatments at local institutions.
Nancy Torres Kaufman, CEO of Beacon Capital, told BioCentury the firm's scientific board will review opportunities for the platform.
President Donald Trump signed S. 204, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try, on May 30 to expand access to investigational drugs that have completed at least Phase I trials for patients with life-threatening diseases (see "Trump Signs Right-to-Try Into Law").